These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 18925849)

  • 1. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
    Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
    Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
    Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.